PTC Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
PTC Therapeutics, Inc. (PTCT) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 5.07% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-19
- PTC Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was 5.07%, a 10.46% increase from fiscal 2023.
- PTC Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 4.59%, a 22.07% decline from fiscal 2022.
- PTC Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was 5.89%, a 30.89% increase from fiscal 2021.
- PTC Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2021 was 4.50%, a 8.72% decline from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | 5.07% 10-K · filed 2026-02-19 |
| 2023-12-31 | 4.59% 10-K · filed 2026-02-19 |
| 2022-12-31 | 5.89% 10-K · filed 2025-02-27 |
| 2021-12-31 | 4.50% 10-K · filed 2024-02-29 |
| 2020-12-31 | 4.93% 10-K · filed 2023-02-21 |
| 2019-12-31 | 4.38% 10-K · filed 2022-02-22 |
| 2018-12-31 | 6.49% 10-K · filed 2021-02-25 |
| 2017-12-31 | 19.53% 10-K · filed 2020-03-02 |
| 2016-12-31 | 16.66% 10-K · filed 2019-03-01 |
| 2015-12-31 | 19.50% 10-K · filed 2018-03-06 |
| 2014-12-31 | 3.78% 10-K · filed 2017-03-16 |
| 2013-12-31 | 15.88% 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |